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Abstract
Background
We characterized associations between smoking, alcohol, and recreational drug use and
coronary plaque by HIV serostatus within the Multicenter AIDS Cohort Study (MACS).
Methods
MACS participants (N = 1005, 621 HIV+ and 384 HIV-) underwent non-contrast CT scan-
ning to measure coronary artery calcium; 764 underwent coronary CT angiograms to evalu-
ate plaque type and extent. Self-reported use of alcohol, tobacco, smoked/inhaled cocaine,
methamphetamine, ecstasy, marijuana, inhaled nitrites, and erectile dysfunction drugs was
obtained at semi-annual visits beginning 10 years prior to CT scanning. Multivariable logis-
tic and linear regression models were performed, stratified by HIV serostatus.
Results
Among HIV+ men, current smoking, former smoking, and cumulative pack years of smoking
were positively associated with multiple coronary plaque measures (coronary artery calcium
presence and extent, total plaque presence and extent, calcified plaque presence, and ste-
nosis >50%). Smoking was significantly associated with fewer plaque measures of compa-
rable effect size among HIV- men; current smoking and calcified plaque extent was the only
such association. Heavy alcohol use (>14 drinks/week) was associated with stenosis >50%
among HIV+ men. Among HIV- men, low/moderate (1–14 drinks/week) and heavy alcohol
use were inversely associated with coronary artery calcium and calcified plaque extent.
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Few significant associations between other recreational drug use and plaque measures
were observed.
Conclusion
Smoking is strongly associated with coronary plaque among HIV+ men, underscoring the
value of smoking cessation for HIV+ persons. Alcohol use may protect against coronary
artery calcium and calcified plaque progression in HIV- (but not HIV+) men. Few positive
associations were observed between recreational drug use and coronary plaque measures.
Introduction
As survival among human immunodeficiency virus (HIV)-infected persons has been markedly
extended through the routine use of potent combination antiretroviral therapy (cART) [1],
non-infectious chronic diseases associated with aging in the general population are more prev-
alent. Multiple studies suggest an increased risk of coronary vascular disease (CVD) among
HIV+ persons compared to the general population despite cART-associated HIV viral suppres-
sion [2–5]. Factors implicated in increased CVD risk among HIV+ persons include chronic
immune activation and inflammation (possibly due to chronic low level viremia), specific ART
drug exposure, and increased prevalence of traditional CVD risk factors [2,3,6–10]. HIV+ per-
sons have an increased prevalence of coronary artery calcium compared to HIV- persons
[5,6,11] and a recent report from our group that evaluated subclinical plaque using CT angiog-
raphy demonstrated higher non-calcified plaque prevalence and extent in HIV+ men com-
pared to HIV- men [12]. Non-calcified plaque, which is lipid-rich, strongly pro-inflammatory,
prone to rupture and thrombosis, and carries a high risk of major coronary events, has previ-
ously been associated with HIV infection using CT angiography [13,14]. Associations between
HIV infection and other plaque types (calcified plaque and mixed plaque, which contains
<50% calcification), which are thought to be more stable and portend lower risk of fatal coro-
nary events than non-calcified plaque [13], are less distinct.
Smoking, alcohol and recreational drug use contribute to CVD development, ranging from
subclinical atherosclerosis to fatal acute coronary syndromes (ACS) [15–20]. Nationally, HIV+
persons are more likely to abuse alcohol and use recreational drugs (notably marijuana, cocaine
and other stimulants) than HIV- persons [21,22]. The detrimental effect of cocaine use on cor-
onary disease pathogenesis has been demonstrated [23,24], and a synergistic effect of cocaine
use and HIV infection on endothelial dysfunction and coronary atherosclerosis has been sug-
gested [25,26]. Otherwise, few data exist regarding specific substance use and CVD risk in the
HIV+ population.
The extent to which smoking, alcohol use and recreational drug use among HIV+ persons
affects CVD risk compared to such use in HIV- persons has not been well-characterized. We
performed a retrospective analysis of prospectively collected data from Multicenter AIDS
Cohort Study (MACS) participants (including previously reported upon coronary CT angiog-
raphy [CTA] data) to investigate associations of alcohol consumption, tobacco use and recrea-
tional drug use with the presence, extent and type of subclinical coronary artery plaque among
HIV+ and HIV- men.
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Methods
The MACS is an ongoing, prospective cohort study evaluating the natural history of treated
and untreated HIV infection [27]. Both HIV+ and HIV- men who have sex with men (MSM)
undergo semiannual standardized interviews, physical examinations and storage and analyses
of blood and urine specimens. Cohort enrollment began in 1984–1985 with further enrichment
in 1987–1991 and in 2001–2003 [27,28].
This analysis included data from participants enrolled in an ancillary cardiovascular study.
Written consent was obtained from all participants, and the study was approved by the institu-
tional review boards at all participating sites (Johns Hopkins Medicine Institutional Review
Board, Baltimore, MD; University of Pittsburgh Institutional Review Board, Pittsburgh, PA;
Northwestern University Institutional Review Board, Chicago, IL; University of California, Los
Angeles Institutional Review Board, Los Angeles, CA). The study included men age 40–70
years, weighing<300 lbs. with no prior history of cardiac surgery or percutaneous coronary
artery intervention. All participants underwent non-contrast cardiac CT scanning for coronary
artery calcium scoring (Agatston score). Men eligible for CTA (absence of atrial fibrillation,
estimated glomerular filtration rate [eGFR]>60 mL/min/m2, absence of history of intravenous
contrast allergy) also underwent CTA scanning to evaluate coronary artery plaque type and
extent [12].
Participant Clinical Parameters
Data regarding substance use and HIV clinical parameters were obtained prospectively from
participants by self-reported history, physical exam and laboratory analysis of blood specimens
collected at each semiannual MACS visit and generally within six months prior to CT scan-
ning. Serum glucose, total, high-density lipoprotein cholesterol and triglyceride levels were
measured from fasting blood samples. Low-density lipoprotein was calculated with the Friede-
wald equation, or measured directly in nonfasting samples or in the presence of triglycerides
>400 mg/dL. Serum creatinine was measured at each MACS visit, and within 30 days prior to
CT scanning for men eligible for IV contrast injection. GFR was calculated using the Modifica-
tion of Diet in Renal Disease equation (MDRD). Diabetes mellitus was defined as fasting
serum glucose>126 mg/dL or the reported use of diabetic medications. Hypertension was
defined as systolic blood pressure (BP)>140 or diastolic BP>90 mmHg, or reported use of
antihypertensive medications. In HIV+ men, plasma HIV RNA levels, CD4+ T-lymphocyte
(CD4) nadir, and history of AIDS-defining illness were included as measures of HIV disease
status. In the MACS, plasma HIV RNA was measured using the COBAS Ultrasensitive Ampli-
cor HIV-1 monitor assay (Roche Molecular Systems, Branchburg, NJ), sensitive to 50 copies
HIV RNA/mL, or Taqman HIV-1 Test (Roche molecular Systems, Branchburg, NJ), sensitive
to 20 copies HIV RNA/mL. CD4 counts were measured using standardized flow cytometry
[29]. AIDS-defining illnesses were identified (or determined) according to the 1993 CDC defi-
nition of AIDS [30]. Body mass index (BMI) was determined at each visit by dividing measured
body weight (kg) by measured height2 (m2). For this analysis, we used clinical data and blood
tests that had been collected at the previous MACS visit closest to the CT scan, generally within
6 months [12].
Substance Use
Substance use was the primary exposure of interest, defined as alcohol consumption, use of
smoked tobacco or recreational drugs. Recreational drug use included stimulants (smoked or
inhaled cocaine, methamphetamines, and ecstasy), marijuana, inhaled nitrites, and erectile dys-
function drugs (EDD; phosphodiesterase inhibitors, including both prescribed medications
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and non-prescribed medications used recreationally for sexual performance enhancement).
EDD were included due to the high prevalence of their use in our cohort and the association
with comorbid use of other recreational substances among MSM [31]. Further, the vasoactive
properties of EDD, increasing nitric oxide production and thus facilitating coronary vasodila-
tion, entrench their inclusion in this analysis. Self-reported use of other substances was
obtained prospectively from semiannual questionnaires performed during the 10-year period
prior to CT scanning. For smoking, questionnaires asked if the participants had ever smoked
cigarettes, if they currently smoke cigarettes, and how many packs they smoke daily. For alco-
hol consumption, questionnaires asked the participants how frequently they drank alcohol
during the previous six months (never, less than monthly, monthly, weekly, daily or almost
daily), and how many drinks they consumed on a typical day when they were drinking. For
other recreational drug use, questionnaires asked the participants if they had used the sub-
stance in question since the previous MACS visit, and if so, how frequently they used the sub-
stance (daily, weekly, monthly, less often).
Alcohol. Use patterns in the 6 months before CT scanning were categorized as none
(reference group), low/moderate use (1–14 drinks/week), and heavy use (>14 drinks/week).
Binge drinking (5 drinks at least once over past 30 days) was included as a separate, distinct
variable.
Tobacco. Smoking was categorized as no use (reference group), current use, or former use
at time of CT scanning, and cumulative pack-years before and up to CT scanning (lifetime
pack-years were analyzed rather than only including the 10-year study period).
Recreational drugs. These use patterns were defined as cumulative years of the substance
used, weighted by frequency of use, during the 10-year study period. Similar to the standard mea-
surement of smoking in pack-years (packs per day, per year), we determined use-years for each
of the other recreational substances. Since recreational substances were likely to be used less fre-
quently than tobacco, use-years for recreational drugs were standardized to monthly use (as
opposed to daily use as with tobacco smoking). Thus, use-years were characterized as use of drug
per month, per year. For example, if an individual reported daily use of a substance during the
last six months, then his use was calculated as 30.5 days per month x 0.5 years = 15.25 years of
monthly use (or 15.25 use-years). Alternatively, if the individual used the same substance once
monthly, then his use was calculated as 1 day per month x 0.5 years = 0.5 use-years (similar
conceptually to pack-years of smoking; if the individual smoked 1 pack daily over six months, his
calculated average use is 0.5 pack-years). Using this method of calculating use-years at each semi-
annual study visit, cumulative use over the 10-year study period was determined (for further dis-
cussion on cumulative use of recreational drugs methodology, see Appendix).
CT Scanning
Procedural details of the cardiac CT scanning have been previously described [12,32]. Briefly,
three centers utilized a 64-slice multi-detector CT and one center utilized a 320-row multi-
detector CT. Participants received a beta-blocker or calcium channel blocker as needed
for heart rate control, and sublingual nitroglycerine prior to IV contrast injection unless
contraindicated.
CT and CTA images were analyzed by experienced readers blinded to participant HIV ser-
ostatus at the Los Angeles Biomedical Research Institute at Harbor-UCLA. Coronary artery
segments were analyzed using the 15-segment model of the American Heart Association [33].
The presence, extent and calcium composition of coronary artery plaques, as well as degree of
luminal narrowing, were assessed in all measurable segments. Plaque size was graded as 0 = no
plaque, 1 = mild, 2 = moderate, or 3 = severe. Segment stenosis was defined as 0 = no plaque,
Substance Use, Coronary Plaque, and HIV Status
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1 = 1–29% (minimal) stenosis, 2 = 30–49% (mild) stenosis, 3 = 50–69% (moderate) stenosis, or
4 for70% (severe) stenosis. The total plaque score was calculated by summing the plaque
size score for all assessable coronary segments that demonstrated any plaque (either calcified,
non-calcified, or mixed) up to a maximum score of 45. Plaques were classified as calcified
(>130 Hounsfield Units visualized as separate from the vessel lumen in at least two indepen-
dent planes), non-calcified (discernible intraluminal structures assigned to a vessel wall with
CT density less than that of the intravascular contrast but greater than that of the surrounding
connective tissue), and mixed (<50% of the plaque occupied by calcium). Total plaque scores
were produced by the summation of plaque scores in each calcified, non-calcified, and mixed
plaque segments separately.
Statistical Analysis
Since factors associated with plaque presence (present vs. absent) and extent (plaque scores
greater than zero) may differ, they were treated as separate outcomes. Separate multiple logistic
regression models were performed to evaluate associations between substance use and plaque
presence for coronary artery calcium, total plaque, calcified plaque, non-calcified plaque,
mixed plaque, and coronary artery stenosis>50%. Those with coronary artery calcium or pla-
que presence (that is to say, presence of subclinical atherosclerosis as determined by coronary
artery calcium, total plaque, calcified plaque, non-calcified plaque, and mixed plaque scores
above zero), underwent further analysis by linear regression to evaluation associations between
substance use and plaque extent (in other words, severity of subclinical atherosclerosis). Since
distributions of plaque scores were not normally distributed, these values were natural-log
transformed for analysis. For each outcome, we conducted two models: one included current
or past smoking and all other substance use variables, and the other used cumulative years of
smoking to replace current or past smoking variables. All models were performed stratified by
HIV serostatus and adjusted for age, race, study center (Baltimore, Pittsburgh, Chicago, or Los
Angeles), cohort status (enrolled pre- or post-2001), education ( college or not), and estab-
lished CAD risk factors (use of hypertension or diabetes or lipid-lowering medications, systolic
BP, fasting glucose, total cholesterol, and body mass index). The full, non-stratified models also
included interaction terms to evaluate the shared effect of smoking and HIV infection on pla-
que presence and extent. In models evaluating HIV+ men alone, HIV clinical parameters
(nadir CD4 count, detectable HIV RNA status, and history of AIDS-defining illness) were
included. Multiple imputation was used to complete missing covariates for multiple regression
models, with subsequent adjustment for the imputed data. For each outcome, the multiple
imputation included all predictors and the outcome. Missing values were imputed five times
based on the distribution of covariates using a Markov chain Monte Carlo (MCMC) method
[34] assuming multivariate normality. Values for the following number of men were missing
and imputed for multiple regression analyses: hypertension medications (14), systolic blood
pressure (7), diabetes medications (16), fasting glucose (31), lipid medications (30), total cho-
lesterol (4), body mass index (14), and current or past smoking (9). All statistical analyses were
performed using SAS 9.3 (SAS Institute, Cary, NC). The statistical power of different compari-
sons, as different groups contain different numbers of participants, may have varied, however
as this is a multiple regression analysis using observational data, formal power analyses were
not performed, as is standard procedure.
Results
There were 1005 men (621 HIV+ and 384 HIV-) who underwent non-contrast CT scanning to
measure coronary artery calcium. Of these, 764 (453 HIV+ and 311 HIV-) had coronary CT
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angiograms. Participant characteristics are summarized on Table 1. Compared to HIV- men,
HIV+ men were younger, more likely to be African American, and less likely to have college
degree. HIV+ men had greater pack-years of smoking, were more likely to be current smokers,
more likely to binge drink, and to use stimulants and inhaled nitrites.
Among HIV+ men, current smoking was positively associated with the presence of coro-
nary artery calcium, total plaque, calcified plaque and coronary artery stenosis>50% (OR
[95% CI] 2.3 [1.3–3.9], 2.3 [1.1–4.7], 2.0 [1.1–3.9], 2.6 [1.1–6.0]) (Table 2), and with extent of
coronary artery calcium (β [SE] 0.96 [0.27]) (Table 3). Former smoking was positively associ-
ated with presence of calcified plaque and stenosis (OR 2.2 [1.2–3.8], 2.2 [1.1–4.7]) (Table 2),
and with extent of coronary artery calcium and total plaque (β 0.72 [0.23], β 0.24 [0.11])
(Table 3). Heavy alcohol use was positively associated with presence of stenosis (OR 4.7 [1.5–
14.8]) (Table 2). Cumulative pack-years of smoking and EDD use were also significantly
associated with multiple plaque measures, but with negligible effect sizes (Tables 2 and 3). No
significant associations were apparent between plaque presence or extent and marijuana, stim-
ulant or nitrite use among HIV+ men. There was an interaction of former smoking and HIV
infection status with calcified plaque presence (p = 0.014) and coronary artery calcium extent
(p = 0.009).
Among HIV- men, current smoking was positively and significantly associated with calci-
fied plaque extent only (β 0.49 [0.23]), however it is noteworthy that non-significant associa-
tions between current smoking and all plaque end-points, except non-calcified plaque,
demonstrated large effect sizes similar in magnitude to those seen among HIV+ men (Tables
4 and 5). No associations were observed among former smokers. Cumulative pack-years of
smoking was significantly associated with presence of coronary artery calcium, stenosis, and
total plaque extent, while marijuana use was significantly associated with coronary artery cal-
cium extent and stimulant use with total plaque presence, but all of these associations had neg-
ligible effect sizes (Tables 4 and 5). Moderate and heavy alcohol use were inversely associated
with coronary artery calcium extent (β -0.69 [0.28], β -1.14 [0.51]), heavy alcohol use was
inversely associated with calcified plaque extent (β -0.89 [0.27]) and binge drinking was posi-
tively associated with calcified plaque extent (β 0.85 [0.37]) (Table 5). No statistically signifi-
cant associations between plaque and EDD or nitrite use were seen among HIV- men.
Discussion
In this well-characterized group of HIV+ and HIV- men who underwent CT evaluation of cor-
onary plaque, cigarette smoking was positively associated with more measures of subclinical
atherosclerosis presence and extent with large effect sizes among HIV+ men than among HIV-
men. Among HIV+ men, current smoking was associated with presence of coronary artery
calcium, any plaque, calcified plaque, coronary stenosis>50%, and extent of coronary artery
calcium. Past smoking was associated with presence of calcified plaque and stenosis, as well as
extent of coronary artery calcium and total plaque. There was a positive interaction between
HIV infection and past smoking on calcified plaque presence and coronary artery calcium
extent, suggesting a unique synergistic effect on these plaque endpoints. Among HIV- men,
current smoking was associated with calcified plaque extent, though no other significant inter-
actions with a large magnitude of effect were evident. Non-significant associations, but with
large effect sizes, were noted between current smoking and presence of coronary artery cal-
cium, total plaque, calcified plaque, mixed plaque and stenosis>50% among HIV- men; this
indicates a potential non-significant trend of positive association between current smoking and
each plaque type except for non-calcified plaque, however the non-statistical significance
might also be due to smaller sample size than the HIV+ group. Nonetheless, we did observe a
Substance Use, Coronary Plaque, and HIV Status
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Table 1. Participant Characteristics and Plaque/Stenosis Prevalence.
Non-contrast CT p-value Non-contrast CT and CT-
angiogram
p-value
HIV+ HIV- HIV+ HIV-
N = 621 N = 384 N = 453 N = 311
Age in years, Median (IQR) 53(48–58) 55(50–62) <0.001 52(47–57) 55(50–62) <0.001
Race <0.001 <0.001
Caucasian (%) 52.7 66.9 50.1 68.5
African American (%) 34 24.7 34.7 23.8
Hispanic/Other (%) 13.4 8.3 15.2 7.7
Education with college degree (%) 43.2 59.9 <0.001 42.6 61.1 <0.001
Systolic BP, mmHg, Median (IQR) 126(115–137) 128(118–137) 0.25 126(115–136) 128(118–137) 0.095
LDL cholesterol, mg/dL, Median (IQR) 104(81–128) 112(91–137) <0.001 104(82–134) 113(91–139) 0.001
HDL cholesterol, mg/dL, Median (IQR) 46(38–55) 52(43–61) <0.001 45(37–55) 52(43–61) <0.001
Taking BP medication (%) 35.9 31.2 0.132 32.1 29.8 0.51
Taking DM medication (%) 8.7 7.6 0.55 7.8 6.5 0.5
Taking cholesterol medication (%) 34.9 30.1 0.12 33.7 31.6 0.54
HIV clinical factors
Nadir CD4 (cells/μL), Median (IQR) 248(144–336) — 256(159–340) —
History of AIDS (%) 14.2 — 11 —
HIV RNA >50 copies/mL (%) 17.9 — 19.6 —
Substance use prevalence
Smoking status 0.004 0.005
Never (%) 25.2 25.3 26.2 23.8
Former (%) 43.8 52.9 43.5 54.7
Current (%) 31.0 21.8 30.4 21.5
Pack years of smoking, Median (IQR) 5.6(0–22.9) 1.8(0–21.5) 0.018 5.6(0–21.4) 3.1(0–21.9) 0.19
Any ETOH use 1–14 drinks/week (%) 71.7 78.1 0.026 72.8 81 0.005
Any ETOH use >14 drinks/week (%) 21.4 26.8 0.049 23 27.3 0.17
Any binge drinking/week (%) 31.2 25.5 0.052 33.3 26.4 0.04
Any stimulant use (%) 44.8 31.0 <0.001 47.7 30.9 <0.001
Cumulative years of stimulant use, Median (IQR) 3.4(0.6–17.4) 2.5(0.7–15.8) 0.666 3.7(0.7–17.3) 2.4(0.7–14.5) 0.294
Any marijuana use (%) 58.8 54.9 0.23 59.8 55.3 0.21
Cumulative years of marijuana use, Median (IQR) 3.7(0.7–29.5) 2.7(0.5–22.1) 0.321 3.9(0.6–31.2) 2.9(0.6–19.9) 0.615
Any inhaled nitrite use (%) 50.1 40.6 0.003 52.1 40.8 0.002
Cumulative years of inhaled nitrite use, Median (IQR) 2.5(0.5–11.4) 2(0.5–9.8) 0.581 2.6(0.5–13.4) 2.1(0.5–14.5) 0.418
Any EDD use (%) 48.8 45.6 0.32 48.3 44.1 0.24
Cumulative years of EDD use, Median (IQR) 3.1(1.1–6.3) 2.5(1–5.8) 0.198 2.9(1.1–6) 2.6(1–5) 0.383
Plaque/Stenosis Prevalence (%)
Prevalence of coronary artery calcium 53.1 52.1 0.74 — —
Prevalence of any plaque — — 77.7 74.6 0.32
Prevalence of calcified plaque — — 34.9 39.9 0.16
Prevalence of non-calcified plaque — — 63.1 52.7 0.004
Prevalence of mixed plaque — — 34.7 31.8 0.47
Prevalence of coronary artery stenosis >50% — — 16.8 14.5 0.39
doi:10.1371/journal.pone.0147822.t001
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significant positive interaction between HIV infection and past smoking on calcified plaque
presence and coronary artery calcium extent, as stated above. While prior cross-sectional stud-
ies have demonstrated associations between coronary artery calcium and HIV infection [5,11],
our observed differential associations of smoking with subclinical atherosclerosis by HIV seros-
tatus are novel.
The prevalence of tobacco smoking among HIV+ persons is higher than in the general pop-
ulation [35]. Increased risk for CVD already exists among HIV+ persons [2], and HIV+ smok-
ers have been estimated to carry twice the risk of a major cardiovascular event compared to
HIV+ nonsmokers [36]. HIV infection and smoking independently trigger an inflammatory
cascade in which endothelial activation, smooth muscle and fibroblast proliferation, and even-
tual endothelial dysfunction and plaque deposition take place [8,37], possibly accounting for
this increased CVD risk. Variations in calcium composition among plaque can affect the clini-
cal course of atherosclerosis; calcified plaque likely represents more long-standing, stable pla-
que, while non-calcified plaque may be newer plaque that is more prone to rupture [13,38].
Our group has recently demonstrated that HIV-infection is associated with a greater
Table 2. Associations Between Substance Use and Presence of each Plaque Type in HIV+ Men.
Substance Total Agatston
Score >0
Total Plaque
Score >0
Total Calcified
Plaque Score >0
Total Non-calcified
Plaque Score >0
Total Mixed
Plaque Score >0
Stenosis
>50%
N = 621 N = 453 N = 453 N = 453 N = 453 N = 453
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Current smoking# 2.26** (1.31–
3.88)
2.27* (1.11–
4.67)
2.03* (1.07–3.85) 1.6 (0.88–2.93) 1.75 (0.93–3.29) 2.55* (1.09–
6.0)
Past smoking# 1.59 (0.99–2.53) 1.63 (0.88–
3.02)
2.17** (1.24–3.78) 1.22 (0.72–2.06) 1.46 (0.85–2.51) 2.22* (1.05–
4.7)
Cumulative pack-
years†
1.02** (1.01–
1.03)
1.03** (1.01–
1.05)
1.02** (1.01–1.03) 1.0 (0.99–1.02) 1.01* (1.0–1.02) 1.01 (1–1.03)
Drinking 1–14 drinks/
week#
1.13 (0.73–1.76) 0.87 (0.47–
1.62)
1.18 (0.71–1.97) 0.74 (0.45–1.22) 1.14 (0.69–1.89) 1.04 (0.54–
2.0)
Drinking >14 drinks/
week#
2.01 (0.75–5.4) 1.93 (0.36–
10.23)
1.04 (0.37–2.92) 2.12 (0.64–7.05) 2.4 (0.87–6.59) 4.71** (1.5–
14.76)
Binge drinking& 1.24 (0.52–2.95) 1.23 (0.35–
4.27)
2.62 (0.95–7.23) 0.52 (0.18–1.47) 1.74 (0.65–4.69) 1.13 (0.31–
4.08)
Cumulative stimulant
use‡
1.0 (0.99–1.01) 1.0 (0.99–1.01) 0.99 (0.98–1.01) 0.52 (0.18–1.47) 1.0 (1.0–1.01) 1.0 (0.96–
1.01)
Cumulative
marijuana use‡
1.0 (1.0–1.01) 1.0 (1.0–1.01) 1.0 (1.0–1.004) 1.0 (0.99–1.01) 1.0 (1.0–1.004) 1.0 (1.0–
1.004)
Cumulative inhaled
nitrite use‡
1.0 (0.99–1.01) 1.0 (0.99–1.01) 1.0 (1.0–1.01) 1.0 (1.0–1.002) 1.0 (0.99–1.01) 1.0 (1.0–1.01)
Cumulative EDD use‡ 1.01 (0.94–1.09) 0.95 (0.85–
1.06)
1.01 (0.93–1.09) 1.0 (0.99–1.01) 1.06 (0.98–1.15) 1.05 (0.95–
1.15)
*p 0.05
**p 0.01
#compared to no-use
&compared to non-binge drinking
†per pack-year (packs per day, per year)
‡per use-year (days of use per month, per year)
Model was adjusted for age, race, study center (Baltimore, Pittsburgh, Chicago, or Los Angeles), cohort status (enrolled pre- or post-2001), education
( college or not), and established CAD risk factors (use of hypertension or diabetes or lipid-lowering medications, systolic BP, fasting glucose, total
cholesterol, and body mass index)
doi:10.1371/journal.pone.0147822.t002
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prevalence and extent of non-calcified plaque [12]. In the current study, however, we observed
significant associations of smoking with calcified plaque prevalence and extent yet no signifi-
cant associations with non-calcified plaque presence or extent among HIV+ men. Tobacco use
may exert a modifying effect upon plaque among HIV+ men, predisposing plaque to calcium
deposition, or selectively increasing the likelihood of calcified plaque formation. Furthermore,
while the MACS cardiovascular study did not identify a significant association between HIV
infection and stenosis>50% after adjusting for CVD risk factors including pack-years of smok-
ing [12], our current findings suggest that current or past smoking among HIV+ men is signifi-
cantly associated with stenosis>50%. Our more numerous observed associations between
smoking and plaque presence and extent among HIV+ men support a hypothesis that HIV
infection and tobacco use exert a synergistic effect in promoting atherosclerosis development.
Our findings underscore the importance of effective smoking cessation strategies targeting
HIV+ persons to decrease CVD burden. Among HIV+ smokers, mostly small clinic-based ran-
domized control trials of intensive counseling, group therapy, and combined nicotine replace-
ment therapy have been reported, demonstrating inconsistent cessation rates and no follow-up
beyond 6 months [39–42]. A recent randomized trial demonstrated higher abstinence rates at
48 weeks associated with varenicline use compared to placebo (17.6% vs 7.2%, respectively)
[43], suggesting effectiveness of this smoking cessation strategy for HIV+ persons. Smoking
Table 3. Associations Between Substance Use and Extent of each Plaque Type in HIV+ Men.
Substance Total Agatston
Score
Total Plaque
Score
Total Calcified Plaque
Score
Total Non-calcified Plaque
Score
Total Mixed Plaque
Score
N = 330 N = 352 N = 158 N = 286 N = 157
β (SE) β (SE) β (SE) β (SE) β (SE)
Current smoking# 0.96** (0.27) 0.24 (0.13) 0.28 (0.2) -0.07 (0.12) 0.13 (0.18)
Past smoking# 0.72** (0.23) 0.24* (0.11) 0.043 (0.17) 0.06 (0.11) 0.22 (0.16)
Cumulative pack-years† 0.01 (0.004) 0.01* (0.002) 0.01** (0.003) -0.001 (0.002) 0.01 (0.003)
Drinking 1–14 drinks/
week#
0.07 (0.21) -0.02 (0.1) -0.04 (0.15) -0.01 (0.1) 0.06 (0.14)
Drinking >14 drinks/
week#
0.44 (0.38) 0.35 (0.2) 0.34 (0.29) 0.34 (0.19) -0.28 (0.26)
Binge drinking& 0.57 (0.4) 0.27 (0.22) 0.15 (0.28) -0.03 (0.25) 0.26 (0.29)
Cumulative stimulant
use‡
0.001 (0.01) -0.002 (0.002) 0.001 (0.01) -0.002 (0.002) 0.001 (0.003)
Cumulative marijuana
use‡
-0.001 (0.001) 0 (0.001) 0 (0.001) 0 (0.001) 0 (0.001)
Cumulative inhaled nitrite
use‡
-0.004 (0.003) -0.001 (0.002) -0.001 (0.002) -0.001 (0.002) 0.001 (0.002)
Cumulative EDD use‡ 0.03 (0.03) 0.02 (0.02) 0.06* (0.02) 0.001 (0.02) -0.01 (0.02)
*p 0.05
**p 0.01
#compared to no-use
&compared to non-binge drinking
†per pack-year (packs per day, per year)
‡per use-year (days of use per month, per year)
Model was adjusted for age, race, study center (Baltimore, Pittsburgh, Chicago, or Los Angeles), cohort status (enrolled pre- or post-2001), education
( college or not), and established CAD risk factors (use of hypertension or diabetes or lipid-lowering medications, systolic BP, fasting glucose, total
cholesterol, and body mass index)
doi:10.1371/journal.pone.0147822.t003
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cessation strategies have been shown to be less effective among persons using other recreational
drugs [44,45], and HIV+ persons tend to use recreational drugs at higher rates than the general
population, especially if they are smokers [21,22,44]. Thus, polysubstance use among HIV+
persons may be a significant barrier to quitting smoking.
Moderate (and even heavy) alcohol use has been associated with a protective effect against
fatal and non-fatal cardiovascular events in the general population [46–50]. However, alcohol
may also be pro-atherosclerotic with heavy use, causing oxidative damage, smooth muscle pro-
liferation and impairment of endothelial repair mechanisms [51]. Increased coronary artery
calcium prevalence has been observed in association with increasing self-reported alcohol use
in the general population [52]. Our findings support a role for low/moderate and even heavy
alcohol in the protection from coronary artery calcium and calcified plaque progression among
HIV- men that was not observed among HIV+ men. Mechanisms accounting for these differ-
ential associations by HIV serostatus are unclear. Since alcohol consumption has been associ-
ated with lower levels of inflammation in HIV- adults without CVD [53], HIV infection may
sufficiently alter the coronary vascular endothelial milieu through enhanced inflammation
and immune activation to offset protective effects of alcohol use and/or to enhance alcohol’s
Table 4. Associations Between Substance Use and Presence of each Plaque Type in HIV- Men.
Substance Total Agatston
Score >0
Total Plaque
Score >0
Total Calcified
Plaque Score >0
Total Non-calcified
Plaque Score >0
Total Mixed
Plaque Score >0
Stenosis
>50%
N = 384 N = 311 N = 311 N = 311 N = 311 N = 311
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Current smoking# 1.85 (0.82–4.18) 1.76 (0.63–4.9) 2.04 (0.83–5.02) 0.84 (0.38,1.86) 1.79 (0.7–4.48) 2.55 (0.76–
8.63)
Past smoking# 0.93 (0.51–1.71) 0.92 (0.43–
1.95)
0.71 (0.36–1.38) 0.77 (0.43–1.39) 0.95 (0.47–1.92) 1.21 (0.48–
3.08)
Cumulative pack-
years†
1.02* (1.0–1.03) 1.01 (0.98–
1.03)
1.01 (1.0–1.03) 0.99 (0.98–1) 1.01 (0.99–1.03) 1.02* (1.0–
1.04)
Drinking 1–14 drinks/
week#
1.18 (0.67–2.08) 1.24 (0.61–
2.51)
0.96 (0.51–1.78) 0.88 (0.51–1.53) 0.79 (0.42–1.48) 0.59 (0.25–
1.4)
Drinking >14 drinks/
week#
0.83 (0.33–2.11) 2.55 (0.69–
9.45)
1.09 (0.38–3.11) 1.58 (0.61–4.13) 0.46 (0.14–1.46) 0.68 (0.16–
2.89)
Binge drinking& 0.44 (0.13–1.46) 0.48 (0.13–
1.76)
0.33 (0.09–1.2) 0.61 (0.21–1.71) 0.33 (0.08–1.46) 2.23 (0.49–
10.1)
Cumulative stimulant
use‡
1.02 (1.0–1.04) 1.04* (1.001–
1.08)
1.02 (1.0–1.04) 1.0 (1.0–1.02) 1.01 (0.99–1.03) 0.99 (0.97–
1.02)
Cumulative
marijuana use‡
1.0 (1.0–1.0) 1.0 (0.99–1.01) 1.0 (0.99–1.004) 1.0 (1.0–1.01) 1.0 (1.0–1.01) 1.0 (1.0–
1.01)
Cumulative inhaled
nitrite use‡
1.01 (1.0–1.03) 1.0 (0.98–1.02) 1.0 (0.98–1.02) 1.01 (0.99–1.02) 1.0 (1.0–1.02) 1.0 (0.98–
1.02)
Cumulative EDD use‡ 1.03 (0.93–1.14) 0.93 (0.81–
1.06)
0.99 (0.89–1.11) 0.96 (0.87–1.07) 1.03 (0.92–1.16) 0.87 (0.73–
1.04)
*p 0.05
#compared to no-use
&compared to non-binge drinking
†per pack-year (packs per day, per year)
‡per use-year (days of use per month, per year)
Model was adjusted for age, race, study center (Baltimore, Pittsburgh, Chicago, or Los Angeles), cohort status (enrolled pre- or post-2001), education
( college or not), and established CAD risk factors (use of hypertension or diabetes or lipid-lowering medications, systolic BP, fasting glucose, total
cholesterol, and body mass index)
doi:10.1371/journal.pone.0147822.t004
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pro-atherosclerotic effects. While no conclusions regarding the effects of low/moderate alcohol
use upon coronary plaque formation among HIV+ men can be drawn from this study, our
findings suggest that among HIV+ men, heavy alcohol consumption may be harmful. It is
important to note that heavy drinking and binge drinking are not mutually inclusive (several
subjects, for instance, drank>5 drinks in one episode and were thus classified as binge drink-
ers, yet overall consumed<14 drinks/week). The episodic and inconstant nature of binge
drinking therefore likely contributes to inter-group variability in alcohol exposure between the
HIV+ and HIV- binge drinkers, and heavy drinking and binge drinking in these and other
analyses should be interpreted separately.
Use of other recreational drugs was not clearly associated with subclinical atherosclerosis.
Only erectile dysfunction drug use (in HIV+ men), stimulant and marijuana use (in HIV-
men) were positively associated with coronary artery plaque presence or extent, all with very
small magnitudes of effect. It is possible that associations were diminished by coincident
tobacco smoking, which was prevalent in both groups. Other than cocaine, none of the other
recreational drugs we studied are known to be directly pro-atherosclerotic in the general popu-
lation. Nonetheless, other recreational substance use may contribute to CVD risk indirectly by
decreasing efficacy of smoking cessation strategies.
Table 5. Associations Between Substance Use and Extent of each Plaque Type in HIV- Men.
Substance Total Agatston
Score
Total Plaque
Score
Total Calcified Plaque
Score
Total Non-calcified Plaque
Score
Total Mixed Plaque
Score
N = 200 N = 232 N = 124 N = 164 N = 99
β (SE) β (SE) β (SE) β (SE) β (SE)
Current smoking# 0.61 (0.42) 0.28 (0.17) 0.49* (0.23) -0.08 (0.16) -0.07 (0.31)
Past smoking# -0.36 (0.31) -0.02 (0.131) -0.14 (0.18) 0.11 (0.12) -0.26 (0.23)
Cumulative pack-years† 0.01 (0.01) 0.01* (0) 0.01 (0.004) 0.004 (0.003) 0 (0.004)
Drinking 1–14 drinks/
week#
-0.69* (0.28) -0.16 (0.12) -0.22 (0.15) 0.03 (0.11) -0.34 (0.2)
Drinking >14 drinks/
week#
-1.14* (0.51) -0.32 (0.2) -0.89** (0.27) -0.004 (0.18) -0.47 (0.38)
Binge drinking& 0.70 (0.66) 0.28 (0.24) 0.85* (0.37) 0.36 (0.23) 0.29 (0.53)
Cumulative stimulant
use‡
0 (0.01) 0 (0.003) -0.01 (0.004) -0.003 (0.004) 0.01 (0.01)
Cumulative marijuana
use‡
0.01* (0.002) 0 (0.001) 0 (0.001) 0.001 (0.001) 0 (0.002)
Cumulative inhaled nitrite
use‡
-0.01 (0.01) 0 (0.003) 0 (0.01) 0 (0.003) -0.002 (0.01)
Cumulative EDD use‡ 0.08 (0.05) -0.01 (0.02) 0.03 (0.03) -0.04 (0.02) -0.01 (0.04)
*p 0.05
**p 0.01
#compared to no-use
&compared to non-binge drinking
†per pack-year (packs per day, per year)
‡per use-year (days of use per month, per year)
Model was adjusted for age, race, study center (Baltimore, Pittsburgh, Chicago, or Los Angeles), cohort status (enrolled pre- or post-2001), education
( college or not), and established CAD risk factors (use of hypertension or diabetes or lipid-lowering medications, systolic BP, fasting glucose, total
cholesterol, and body mass index)
doi:10.1371/journal.pone.0147822.t005
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This study has several limitations. Approximately 75% of all participants were current or
former smokers; the pro-atherosclerotic effects of smoking may have overshadowed effects of
other substance use in coronary plaque development, despite analytic adjustment for smoking.
This may be true for use of smoked and inhaled cocaine use; because such use was relatively
rare in our cohort, our analysis may have been underpowered to see this effect. The differential
associations with smoking and plaque endpoints between the HIV- and HIV+ groups may
have also been influenced by the statistical power of the study. The smaller sample size of the
HIV- group may have contributed to the non-significance of many associations despite having
large effect sizes. Thus, there may be a trend of positive association between current smoking
and all plaque types (except for non-calcified plaque) among HIV- men, the significance of
which we were unable to observe, suggesting differences in plaque end-points among HIV+
and HIV- current smokers are not definitive in this study. Further, the larger sample size of the
HIV+ group, compounded by the multiplicity of variables in the analysis, may have led to the
significant associations we observed with very small effect sizes in this group. As such, true dif-
ferences in subclinical atherosclerosis between the groups due to smoking may have been over-
estimated in our study. Furthermore, the self-reported nature of our data, possibly leading to
underreporting, and the inclusion of men only are limitations. As our substance use data relied
on the standardized questionnaire answer choices, we were unable to determine more precise
frequencies of drug use and dose responses. Despite their diversity, MACS participants may
not be generalizable to other MSM in the United States. Nevertheless, our study involved a
large sample size, prospectively-collected data over 10 years rather than cross-sectional,
detailed characterization of coronary artery plaque and stenosis, and an HIV- MSM control
group that was similar in most respects to the HIV+ participants, which are all factors that
minimize the likelihood of confounding and selection bias. It is important to note the explor-
atory quality of this observational study, as we are unable to derive clinical significance of these
associations we report. Consequently, longitudinal studies evaluating these plaque end-points
in the setting of substance use are needed to more definitely assess differences of substance use
and subclinical atherosclerosis associations between HIV+ and HIV- men.
Conclusion
HIV+ smokers are particularly vulnerable to CVD, which may reflect independent contribu-
tions of both HIV infection and smoking to inflammatory processes injurious to vascular endo-
thelium. We observed a possible protective effect of low/moderate and heavy alcohol use from
coronary artery calcium and calcified plaque progression in HIV- men but not in HIV+ men.
While we speculate that the chronic inflammatory effects of HIV infection may offset such car-
dio-protective effects of alcohol use, further study is needed. Despite the known detrimental
health consequences of recreational drug use, we did not find conclusive significant associa-
tions with subclinical atherosclerosis; any associations may have been less apparent because of
the potential co-mingling with tobacco smoking. Nevertheless, recreational drug use may con-
tribute to CVD burden indirectly by making smoking cessation more difficult. Collectively, our
findings reinforce the need for effective smoking cessation strategies as a part of CVD preven-
tion, and suggest that this is at least as important, if not more important, an undertaking for
HIV+ smokers.
Appendix
In this study, exposure to recreational drugs was assumed to be cumulative over the last 10
years (20 visits) before CT-scanning. That is, we assumed that the effect of drug use on the out-
comes depended not only on current use, but also on previous use, but only for a period
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corresponding to 10 years. This seemed a reasonable compromise between the two extremes of
using only current exposure and using a cumulative measure like pack-years of smoking that
includes all exposures, no matter how far in the past. Cumulative recreational drug use was cal-
culated for each visit as average number of reported days used per month for a one year period
for stimulants (smoked or inhaled cocaine, methamphetamines, and ecstasy), marijuana,
inhaled nitrites, and erectile dysfunction drugs (EDD; phosphodiesterase inhibitors). This
involved using a measure of quantity or frequency in a given time interval depending on the
wording of the particular question (the weight), during a given period, typically the approxi-
mately six months between visits, normalized to a yearly basis. We constructed a unit of
cumulative use of recreational drugs called use-years (similar to pack-years, the standard mea-
surement of cumulative smoking); use-years for recreational drugs were standardized to
monthly use (as opposed to daily use with tobacco smoking). Thus, use-years were character-
ized as use of drug per month, per year. For the drug use questions, the weights were daily use:
weight = 30.5 (times per month); weekly use: weight = 4.36; monthly use: weight = 1; less often:
weight = 0.33. We then computed cumulative self-reported drug use over the 10-year period
(20 visits) before CT-scan by summing the previous yearly averages at the 20 visits, which pro-
ceeded longitudinally across the 10-year study period. Similarly, additional primary exposure
variables were measured as cumulative amounts per year. This also involved using a measure
of quantity or frequency in a given time interval, depending on the wording of the particular
question, normalized to a yearly basis. For example, if an individual smoked> = 1 but< 2
packs per day in the six months preceding a given visit, then his smoking pack-years exposure
for that visit was calculated as 1.5 (the average of 1 and 2) packs x 0.5 years = 0.75 pack years.
Current exposure was calculated at each visit and cumulated over visits.
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